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Introduction
　Gastric cancer is the second most common cause of cancer related mortality worldwide1）. 
Complete surgical resection, the only potentially curative treatment for advanced gastric 
cancer, can only be performed on a small subgroup of patients.  In 30％ to 50％ of patients 
undergoing surgical exploration, the intent of the surgery is to cure the patient.  However, 
almost 60％ of patients who undergo an R0 curative resection relapse and die of their 
disease 2, 3）.
　Clinical staging is determined using TNM classication : T indicating depth of invasion of 
the primary tumor, N nodal metastasis, and M distant metastasis.  This classication system 
is useful to estimate patient prognosis.  Currently, endoscopic ultrasound（EUS）and com-
puted tomography（CT）are widely used for preoperative tumor staging4）.  The accuracy of 
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nese Classication of Gastric Cancer stages MP, SS, SE）and the relationship 
between CD44s expression and clinicopathological parameters.  CD44s expres-
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staging tumors by determining the T value has been much improved with EUS having an 
accuracy of between 78％-92％ 5-11）, and CT between 69％-89％ 9, 12-18）.
　However, the accuracy of establishing the N category is still poor ; 63％-78％ using 
EUS 5-11） and 51％-78％ using CT9, 12-18）.  The N category estimates 5-year survival rate in 
patients with N0 gastric cancer as 89.4％, but 68.3％ in those with N1 disease 19）.  Thus, 
improving the accuracy of the N value in patients with gastric cancer, could improve the 
accuracy of the preoperative prognosis.
　The transmembrane glycoprotein molecule standard CD44（CD44s）is a cell surface 
hyaluronate receptor, and is expressed in most epithelial and nonepithelial tissues.  The 
clinical signicance of CD44s expression in gastric cancer, however, remains unclear.  Various 
studies have reported an association of CD44s expression with an advanced stages of gastric 
cancer and a poor prognosis20-23）, with one study reporting adverse correlation between 
CD44s expression and tumor progression24-29）.
　The aim of the present study was to evaluate CD44s expression in T2-T3 gastric cancer
（Japanese Classification of Gastric Cancer stages ; muscularis propria MP, subserosa SS, 
serosa exposed SE）and the relationship between CD44s expression and clinicopathologi-
cal parameters.  We thought that it would be possible to improve preoperative prognostic 
precision by using CD44s, if a relationship would be present between CD44s and various 
clinicopathological factors（especially N value）in gastric cancer.
Materials and Methods
　Tissue samples from 98 patients who had T2-T3 primary gastric cancer surgically resected 
at Showa University Hospital from 2004 through 2009 were collected.  Samples were pre-
served in 10％ formalin for 24 h and the nonnecrotic portion of the tumors was routinely 
processed and parafn embedded.  Representative sections were stained with hematoxylin 
and eosin.  Various clinicopathological parameters were evaluated based on the  Japanese 
Classication of Gastric Carcinoma（The 13th Edition, web site : http://www.jgca.jp/PDFles/
JCGC-2E.PDF）.
Immunohistochemistry
　Three micron sections from representative blocks of each case were stained immunohis-
tochemically using monoclonal antibody clone 2C5（anti-CD44s ; R&D Systems, Minneapolis, 
MN, USA）at a dilution of 1 : 500.  The labeled streptavidin-biotin-peroxidase labeling 
technique was used.  Sections were deparaffinized in xylene, dehydrated in descending 
grades（100-50％）of ethanol, and subjected to antigen retrieval（microwave, citrate pH 6.0, 
25 min）.  After cooling to room temperature, slides were incubated to quench endogenous 
peroxidase activity with 1％ hydrogen peroxide in ethanol for 30 min.  Nonspecic immu-
noreactivity was blocked by incubation with normal donkey serum for 30 min each.  The 
sections were then incubated with primary antibody at 4℃ overnight.  After three 5 minute 
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washes with phosphate-buffered saline（PBS）, sections were incubated for 60 min with the 
multilink biotinylated anti-immunoglobulin.  Three 5-minute washes with PBS preceded and 
followed treatment with streptavidin-peroxidase reagent for 30 min.  The reactions were visu-
alized with diaminobenzidine（DAKO A-S, Copenhagen, Denmark）as a chromogen.  Finally, 
sections were counterstained with hematoxylin, dehydrated and mounted.
　CD44s expression was seen as brown, ne to coarse granular staining on the cytoplasmic 
membrane.  Our study aimed to estimate the averaged CD44s expression in the entire 
tumor area, and dened CD44s-positivity to be when more than 10％ of the tumor cells 
was stained（Fig. 1）.  This denition was chosen as it is the most commonly used in the 
literature20, 24, 25）.  And cases were categorized into two groups based on CD44s staining ; the 
CD44s positive group had ＞10％ positively stained tumor cells and the CD44s negative 
group had ＜10％.  All histological slides were examined by two experienced pathologists 
blinded to clinical data or disease outcome.
Statistical analysis
　Association between CD44s expression and clinicopathological parameters was tested using 
the chi-square test, with signicance set at P＜0.05.
Fig. 1.　Sections of gastric tumors stained using CD44s immunohistochemis-
try demonstrating the tumor grading system
A :  Section showing more than 10％ of the tumor cells with positive 
staining for CD44s, and so recorded as a tumor with positive CD44s 
expression. ×400
B :  Section showing lack of CD44s staining of tumor cells, and so recorded 
as a tumor with negative CD44s expression. ×400
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Results
　The characteristics of the study population are shown in Table 1.  The subjects consisted 
of 70 men（71.4％）and 28 women（28.6％）, with a mean age of 69.4 years（range, 45-91 
years）and a mean gastric tumor size of 5.2 cm（range, 1.5-13.8 cm）.
　CD44s expression in the primary tumor was demonstrated in 59.1％（58 / 98）of the 
tumors.  Associations between tumor CD44s expression and the clinicopathological param-
eters of patients and gastric tumors are summarized in Table 1.  No statistically signicant 
differences were found between positive CD44s expression in gastric tumors in patients aged 
less than 60 years（70％）compared with those 60 years or older（56.4％）.  No statistically 
signicant differences were found between positive CD44s expression in gastric tumors in 
male（57.1％）or female patients（64.3％）.  No statistically signicant differences were found 
between positive CD44s expression in gastric tumors occurring in either the lower stomach
（61.9％）or the middle or upper stomach（57.1％）.  Similarly for tumor size, no statistically 
signicant differences were found between positive CD44s expression in gastric tumors less 
Table 1　CD44s expression and clinicopathogical parameters
CD44s expression, n（％）
n＝98 positive＝58（59.2） negative＝40（40.8） p
Age（years）
＜60 20 14（70.0） 6（30.0） 0.396
60 78 44（56.4） 34（43.6）
Gender
Male 70 40（57.1） 30（42.9） 0.673
Female 28 18（64.3） 10（35.7）
Tumor location
UM 56 32（57.1） 24（42.9） 0.789
L 42 26（61.9） 16（38.1）
Tumor size（cm）
＜5.0 50 34（68.0） 16（32.0） 0.108
5.0 48 24（50.0） 24（50.0）
Microscopic classification
tub 56 33（58.9） 23（41.1） 1.00
por, sig 42 25（59.5） 17（40.5）
Invasion depth
T2（MP） 72 43（59.7） 29（40.3） 1.00
T3（SS, SE） 26 15（57.7） 11（42.3）
Lymph node metastasis（N）
N0 38 33（86.8） 5（13.2） ＜0.0001
N1 / 2 60 25（41.7） 35（58.3）
CD44s ; standard CD44
tub ; well differentiated type
por, sig ; poorly differentiated type
MP ; muscularis propria
SS ; subserosa
SE ; serosa exposed
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than 5.0 cm in diameter, compared with tumors 5.0 cm in diameter or greater.  For micro-
scopic tumor type, no statistically signicant differences were found between positive CD44s 
expression in gastric tumors tub1 / tub2（58.9％）or in por / sig（59.5％）.  However, strong 
statistical signicance was found in the association between positive CD44 expression and 
lymph node metastases ; positive expression was present in 86.8％ of gastric tumors from 
patients with no detectable lymph node metastasis（classication N0）, but in only 41.6％ 
of patients with lymph node metastasis（classication N1 / 2）（P＜0.0001）.  Thus, CD44s 
expression in gastric tumors had a signicantly negative relationship with the presence of 
lymph node metastasis in the patient.
Discussion
　CD44 is a large family of cell surface transmembrane glycoproteins whose members 
have different extracellular domains as a result of alternative gene splicing 30, 31）.  CD44s is 
a receptor for hyaluronate and is highly expressed on human lymphocytes.  In malignant 
tumors originating from various organs, there is some controversy as to whether CD44s 
acts as a growth / invasion-promoting molecule or tumor suppression cofactor.  While a 
number of studies have shown that CD44s expression is associated with metastasis and a 
poor patient prognosis21）, others have shown that down-regulation of CD44s expression is 
correlated with an adverse patient outcome.  For example, reduced CD44s expression has 
been shown to be associated with a high incidence of lymphatic or vascular inltration in 
endometrial carcinoma 26） and breast carcinoma24）, and a poor prognosis in patients with 
pancreatic carcinoma, thyroid carcinoma, and squamous cell carcinoma of the head and 
neck 27, 28）.  These differences in study ndings may be due to the use of different antibodies, 
immunohistochemistry methods, patient material, and duration of patient follow-up.
　Similarly, the clinical signicance of CD44s expression in the progression and metastasis of 
malignant gastric tumor is also controversial.  However, Montgomery et al reported that loss 
of CD44s expression in gastric stromal tumors was consistent with tumor aggressiveness 29）, 
and Joo et al found a signicant relationship between CD44s expression and lymph node 
metastasis in gastric cancer22）.  Further, Mayer et al demonstrated expression of CD44s was 
signicantly positively associated with recurrence of gastric adenocarcinoma, distant metastasis 
and patient mortality 23）.  These ndings have been speculated to be due to CD44s activa-
tion of p185 tyrosine kinase and c-Src kinase, interactions which are important in tumor 
progression29）.
　Our study found an adverse relationship between CD44s expression and lymph node 
metastasis in T2-T3 gastric cancer.  This nding may be due to  the loss of CD44s expres-
sion and hence, reduced intercellular adhesion and adhesion between cells and basement 
membranes.  This could facilitate detachment of tumor cells from their primary sites and 
allow inltration of lymphatic or vascular spaces32）.
　The results of this study support a role for CD44s in the inhibition of metastasis of 
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gastric tumor cells to lymph nodes.  This possible suppression of gastric tumor metastasis by 
CD44s may result from its role in binding gastric tumor cells to the extracellular matrix in 
the gastric muscularis propria and subserosal layers and thus restricting cancer cell spread.
　CD44s expression may thus be a useful prognostic indicator in cases with gastric cancer, 
and may facilitate patient-specic tailoring of treatment options, such as the use of chemo-
therapy.
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